主要文件

查看所有文档

1420006

USP

Levodopa Related Compound B

Name: Levodopa Related Compound B
Brand: USP

United States Pharmacopeia (USP) Reference Standard

别名:

DL-3-O-Methyldopa, 3-Methoxytyrosine

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₁₀H₁₃NO₄

化学文摘社编号:

7636-26-2

分子量:

211.21

MDL number:

MFCD00063077

UNSPSC Code:

41116107

NACRES:

NA.24

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

属性

grade

pharmaceutical primary standard

API family

levodopa

manufacturer/tradename

USP

application(s)

pharmaceutical (small molecule)

format

neat

storage temp.

2-8°C

SMILES string

NC(Cc1cc(c(cc1)O)OC)C(=O)O

InChI

1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)

InChI key

PFDUUKDQEHURQC-UHFFFAOYSA-N

说明

General description

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:

Carbidopa and Levodopa Orally Disintegrating Tablets
Levodopa
Carbidopa and Levodopa Tablets
Carbidopa and Levodopa Extended-Release Tablets

Analysis Note

These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.

Other Notes

Sales restrictions may apply.

Still not finding the right product?

Explore all of our products under

存储类别

11 - Combustible Solids

wgk

WGK 3

flash_point_f

No data available

flash_point_c

No data available

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our 文件 section.

如需帮助，请联系客户支持

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Pharmacokinetics of levodopa, carbidopa, and 3-O-methyldopa following 16-hour jejunal infusion of levodopa-carbidopa intestinal gel in advanced Parkinson's disease patients.

Dag Nyholm et al.

The AAPS journal, 15(2), 316-323 (2012-12-12)

Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy. Levodopa-carbidopa intestinal gel (LCIG) is infused continuously via an intrajejunal percutaneous gastrostomy tube. This was the first study designed to characterize the

Methyl group-donating vitamins elevate 3-O-methyldopa in patients with Parkinson disease.

Thomas Müller et al.

Clinical neuropharmacology, 36(2), 52-54 (2013-03-19)

Levodopa (LD)/dopa decarboxylase inhibitor application increases 3-O-methyldopa (3-OMD) concentrations in association with methyl group transfers, which demand for the conversion of methionine to homocysteine. This accompanying reaction is partially reversible by methyl group-donating vitamins. The objective of this study was

Acute levodopa administration reduces cortisol release in patients with Parkinson's disease.

T Müller et al.

Journal of neural transmission (Vienna, Austria : 1996), 114(3), 347-350 (2006-08-26)

Levodopa (LD) application improves motor symptoms in patients with Parkinson's disease (PD) patients. Little is known on further effects of LD, which induced lower plasma levels of cortisol and lower serotonergic activity in certain brain areas of fish. Objectives of

查看所有相关文献

全球贸易项目编号

货号	GTIN
1420006-50MG	04061833860533